Kenneth Galbraith's most recent trade in Zymeworks BC Inc was a trade of 222,000 Performance Stock Unit done . Disclosure was reported to the exchange on Jan. 12, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2026 | 222,000 | 222,000 | - | - | Performance Stock Unit | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2026 | 216,000 | 216,000 | - | - | Stock Option (Right to Buy) | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2026 | 144,000 | 144,000 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jan 2026 | 64,000 | 257,266 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jan 2026 | 64,000 | 128,000 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Sale of securities on an exchange or to another person at price $ 22.67 per share. | 12 Jan 2026 | 30,424 | 226,842 (0%) | 0% | 22.7 | 689,819 | Common Stock |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2026 | 66,666 | 66,668 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2026 | 66,666 | 224,952 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2026 | 47,668 | 0 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2026 | 47,668 | 180,943 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Sale of securities on an exchange or to another person at price $ 25.10 per share. | 05 Jan 2026 | 31,686 | 193,266 (0%) | 0% | 25.1 | 795,220 | Common Stock |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Sale of securities on an exchange or to another person at price $ 25.10 per share. | 05 Jan 2026 | 22,657 | 158,286 (0%) | 0% | 25.1 | 568,620 | Common Stock |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2025 | 100,000 | 180,803 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2025 | 100,000 | 0 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Sale of securities on an exchange or to another person at price $ 27.02 per share. | 22 Dec 2025 | 47,528 | 133,275 (0%) | 0% | 27.0 | 1,284,311 | Common Stock |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 288,000 | 288,000 | - | - | Stock Option (Right to Buy) | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 192,000 | 192,000 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 66,666 | 114,209 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 66,666 | 133,334 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 47,666 | 71,428 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 47,666 | 47,668 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Sale of securities on an exchange or to another person at price $ 14.92 per share. | 06 Jan 2025 | 33,406 | 80,803 (0%) | 0% | 14.9 | 498,554 | Common Stock |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Sale of securities on an exchange or to another person at price $ 14.92 per share. | 06 Jan 2025 | 23,885 | 47,543 (0%) | 0% | 14.9 | 356,462 | Common Stock |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Zymeworks BC Inc | Galbraith Kenneth | Director, Chair & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 200,000 | 200,000 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Galbraith Kenneth | Director, Chair & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 47,666 | 47,666 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Galbraith Kenneth | Director, Chair & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 47,666 | 95,334 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Galbraith Kenneth | Director, Chair & CEO | Sale of securities on an exchange or to another person at price $ 10.65 per share. | 05 Jan 2024 | 18,198 | 29,468 (0%) | 0% | 10.7 | 193,849 | Common Stock |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Sale of securities on an exchange or to another person at price $ 11.22 per share. | 05 Jan 2024 | 5,706 | 23,762 (0%) | 0% | 11.2 | 63,996 | Common Stock |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 215,000 | 215,000 | - | - | Stock Option (Right to Buy) | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 143,000 | 143,000 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2022 | 100,000 | 100,000 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2022 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Macrogenics Inc | Kenneth Galbraith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) |